222 related articles for article (PubMed ID: 1626611)
1. Drug therapy for inflammatory bowel disease: Part I.
Linn FV; Peppercorn MA
Am J Surg; 1992 Jul; 164(1):85-9. PubMed ID: 1626611
[TBL] [Abstract][Full Text] [Related]
2. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Hanauer SB; Stathopoulos G
Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
[TBL] [Abstract][Full Text] [Related]
3. A practical guide to the management of distal ulcerative colitis.
Ardizzone S; Bianchi Porro G
Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory bowel disease.
Van Rosendaal GM
CMAJ; 1989 Jul; 141(2):113-23; discussion 123-4. PubMed ID: 2568163
[TBL] [Abstract][Full Text] [Related]
5. [Local or systemic treatment of inflammatory bowel diseases?].
Schmassmann A; Halter F
Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
[TBL] [Abstract][Full Text] [Related]
6. Advances in drug therapy for inflammatory bowel disease.
Peppercorn MA
Ann Intern Med; 1990 Jan; 112(1):50-60. PubMed ID: 2152845
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic therapy for inflammatory bowel disease.
Hirschfeld S; Clearfield HR
Am Fam Physician; 1995 Jun; 51(8):1971-5. PubMed ID: 7762487
[TBL] [Abstract][Full Text] [Related]
8. Newer pharmacologic agents for the therapy of inflammatory bowel disease.
Ruderman WB
Med Clin North Am; 1990 Jan; 74(1):133-53. PubMed ID: 2404172
[TBL] [Abstract][Full Text] [Related]
9. Current medical therapy for inflammatory bowel disease.
Bonner GF
South Med J; 1996 Jun; 89(6):556-66. PubMed ID: 8638193
[TBL] [Abstract][Full Text] [Related]
10. [Inflammatory bowel diseases: conservative therapy].
Bansky G
Ther Umsch; 1991 Jul; 48(7):464-70. PubMed ID: 1926006
[TBL] [Abstract][Full Text] [Related]
11. Comparative tolerability of therapies for ulcerative colitis.
Ardizzone S; Bianchi Porro G
Drug Saf; 2002; 25(8):561-82. PubMed ID: 12113642
[TBL] [Abstract][Full Text] [Related]
12. Review article: topical corticosteroids in inflammatory bowel disease.
Mulder CJ; Tytgat GN
Aliment Pharmacol Ther; 1993 Apr; 7(2):125-30. PubMed ID: 8485265
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
Van Gossum A
Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
[TBL] [Abstract][Full Text] [Related]
14. [Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments].
Fischbach W
Leber Magen Darm; 1992 Mar; 22(2):49-55. PubMed ID: 1350043
[TBL] [Abstract][Full Text] [Related]
15. Aminosalicylates: old and new.
Hanauer SB
Mt Sinai J Med; 1990 Oct; 57(5):283-7. PubMed ID: 1982892
[No Abstract] [Full Text] [Related]
16. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.
Järnerot G
Drugs; 1989 Jan; 37(1):73-86. PubMed ID: 2651087
[TBL] [Abstract][Full Text] [Related]
17. [Conservative therapy of ulcerative colitis and Crohn disease].
Rasenack J; Kreisel W
Fortschr Med; 1991 Apr; 109(11):245-7. PubMed ID: 1855750
[TBL] [Abstract][Full Text] [Related]
18. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.
Brzezinski A; Rankin GB; Seidner DL; Lashner BA
Cleve Clin J Med; 1995; 62(5):317-23. PubMed ID: 7586488
[TBL] [Abstract][Full Text] [Related]
19. 5-aminosalicylates in inflammatory bowel disease--the more the merrier?
Forbes A
Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1017-9. PubMed ID: 8680898
[No Abstract] [Full Text] [Related]
20. Tolerability of aminosalicylates in inflammatory bowel disease.
Ishaq S; Green JR
BioDrugs; 2001; 15(5):339-49. PubMed ID: 11437696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
